Citations 2
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Yang, Dongyun , Li, Meng , Groshen, Susan , Stephens, Craig, Kim, Philip H., Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B., Den, Robert B. , Xu, Tong , Xu, Yucheng, Gill, Inderbir S. , Goldkorn, Amir , Wang, Lina , Davicioni, Elai , Quinn, David I , Den, Robert B , Gill, Inderbir S
The Prostate | January 16, 2016 | Volume: 76 | Issue: 6 | Pages: 597-608
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Dueck, Amylou C. , Reinholz, Monica M., Geiger, Xochiquetzal J., Tenner, Kathleen , Jenkins, Robert B., Riehle, Darren, Chen, Beiyun, McCullough, Ann E. , Davidson, Nancy E. , Martino, Silvana, Kutteh, Leila A., Harris, Lyndsay N. , Lingle, Wilma L., Perez, Edith A. , Ballman, Karla V. , Sledge, George W. , Kaufman, Peter A. , Gralow, Julie R. , Ingle, James N. , Dueck, A. C.
Clinical Cancer Research | August 22, 2013 | Volume: 19 | Issue: 20 | Pages: 5798-5807
Abstract Purpose: This study investigated the association between tumor MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) in the N9831 (Alliance) adjuvant HER2+ trastuzumab breast cancer trial. Experimental Design: This analysis included 1,736 patients randomized to Arms A, B, and C on N9831. Nuclear MYC protein expression was determined in tissue microarray sections containing three biopsies per patient or whole tissue sections using standard immunohistochemistry (clone 9E10). A tumor was considered positive for MYC protein overexpression (MYC+) if the nuclear 3+ staining percentage was more than 30%. Results: Five hundred and seventy-four (33%) tumors were MYC+. MYC+ was associated with hormone receptor positivity (χ2, P = 0.006), tumors 2 cm or more (χ2, P = 0.02), and a higher rate of nodal positivity (χ2, P < 0.001). HRs for DFS (median follow-up: 6.1 years) for Arm C versus A were 0.52 (P = 0.006) and 0.65 (P = 0.006) for patients with MYC+ and MYC− tumors, respectively (Pinteraction = 0.40). For Arm B versus A, HRs for patients with MYC+ and MYC− tumors were 0.79 (P = 0.21) and 0.74 (P = 0.04), respectively (Pinteraction = 0.71). For Arm C versus B, HRs for patients with MYC+ and MYC− tumors were 0.56 (P = 0.02) and 0.89 (P = 0.49), respectively (Pinteraction = 0.17). Conclusions: Our data do not support an impact of tumor MYC protein expression on differential benefit from adjuvant trastuzumab. Clin Cancer Res; 19(20); 5798–807. ©2013 AACR.